In KRAS-mutated cancer cells, single agent MEK inhibitor treatment is ineffective because it both relieves ERK-dependent negative feedback signaling and induces the expression of RTK and ligands [96,97,98,99,100,101,102,103,104,105]. This evidence concerns the gene KRAS and cancer.